Attorneyatlaw.com

Audience: Cardiology and endocrinology healthcare professionals
FDA notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of…

Related posts:

1. Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk Audience: Neurology, Cardiology Issue: FDA notified healthcare professionals that it...
2. Benicar (olmesartan): Ongoing Safety Review Audience: Cardiology, Internal Medicine ISSUE: FDA is evaluating data from...
3. Ultram (tramadol hydrochloride), Ultracet (tramadol hydrochloride/acetaminophen): Label Change Audience: Pain management healthcare professionals [Posted 05/25/2010] Ortho-McNeil-Janssen and FDA...
4. GnRH Agonists: Safety Review of Drug Class Used to Treat Prostate Cancer Audience: Urology, Oncology healthcare professionals, patients (sold under the brand...
5. Exjade (deferasirox) – Early Communication Audience: Hematology-Oncology healthcare professionals FDA notified healthcare professionals of an...

Permalink Tags: Dangerous Drugs

This entry was posted on Friday, November 20th, 2009 at 12:00 am and is filed under Dangerous Drugs. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.